Government Price Controls on Obesity Drugs This policy brief discusses the implications of proposed US price controls on drugs for both public and private payers based on the manufacturing costs of producing the medications or foreign prices. We provide an in-depth...
Expediting breakthrough medical device reimbursement has become a recent public policy issue. This paper provides evidence of the value of faster reimbursement of new medical devices using a comprehensive dataset of past approved devices. The estimation considers the...
Proposed “delinking” legislation would prohibit Pharmacy Benefit Managers (PBMs) from being remunerated based on the rebates and discounts they negotiate for drug insurance plans serving Medicare beneficiaries. This policy would significantly change drug pricing and...
A longstanding economic literature argues that the total welfare loss of a disease comes not only from the direct effects of the disease itself, but also the costs of preventing the disease. This paper assesses how new medical innovations for COVID-19—specifically...
Historically, Medicare has reimbursed drugs approved by the Food and Drug Administration (FDA) including drugs granted accelerated approval. In 2021, FDA granted accelerated approval to plaque-targeting treatments for Alzheimer’s disease (AD), but the Centers for...
